Five Prime Therapeutics, Inc.

Bristol-myers Squibb Compnay

Abbvie Biotherapeutics Inc.

Other

Merck Sharp + Dohme Corp.

Bristol-myers Squibb

Diane Hollenbaugh

Ernestine A Lee

Minmin Qin

Elizabeth Bosch

Ali Sadra

Alejandro A Aruffo

Barbara A Thorne

Shiming Ye

Diane Sau Mun Cohen

Lewis T Williams

Stephen Kohl Doberstein

Kevin Hestir

Justin Wong

Hongbing Zhang

Ge Wu

Anthony W Siadak

Jurgen Bajorath

Linda Harris

Karen K Berry

Jeffrey A Ledbetter

Subinay Ganguly

Jill Rillema

Robert S Mittler

Walter W Shuford

Maria Jure Kunkel

Ralph Abraham

Jeffry Dean Watkins

William D Huse

Herren Wu

Joseph A Hedrick

Lisa K Gilliland

Frederick James Monsma, Jr

Tatyana Churakova

Linda J Harris

Marcia L Gordon

Jürgen Bajorath

The present disclosure provides novel anti-CD40 antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.

Anti-CD40 antibody

Anti-CD40 antibodies

Nucleic acid molecules encoding anti-CD40 antibodies

The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.

Methods of treating disease with FGFR1 fusion proteins

FGFR2 fusion proteins comprising C-terminal deletion mutants of FGFR2-IIIC

The present invention provides compositions and methods for treating disorders of cholesterol and lipid metabolism by administration of an anti-PCSK9 antibody or a peptide inhibitor of PCSK9.

Anti-PCSK9 and methods for treating lipid and cholesterol disorders

Polynucleotides encoding FGFR1-IIIc ECD fusion proteins

FGFR2-IIIb fusion proteins and methods of making them

ECD carboxy-terminal deletion FGFR4 fusion proteins and methods of producing them

FGFR3-IIIc fusion proteins

Compositions and methods of treating disease with FGFR fusion proteins

A humanized antibody that binds to human 4-1BB and that allows binding of human 4-1BB to a human 4-1BB ligand. In one aspect, the antibody is an IgG4 antibody. Also provided is a method for treating cancer in a subject comprising administering a therapeutically effective amount of the antibody to said subject.

Polynucleotides encoding humanized antibodies against human 4-1BB

Humanized antibodies against human 4-1BB

Growing community of inventors

Mountain View, CA, United States of America

Diane Hollenbaugh